References
- Sagnier PP, Girman CJ, Garraway M, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29: 15–20.
- Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71.
- Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994; 140: 989–1002.
- Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology 1995; 46: 23–5.
- Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin N Am 1995; 22: 237–46.
- Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118–26.
- Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. J Androl 1996; 17: 2–4.
- Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbj erg A, Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 1997; 158: 222–7.
- Colao AM, Marzullo P, Spiezia S, et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: An ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy sub-jects. J Clin Endocrinol Metab 1999; 84: 1986–99.
- Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83: 775–9.
- Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76: 1115–8.
- Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP. Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm Res 1996; 45: 252–7.
- Weinehall L. Ume5 University Medical Dissertations. ISSN 0346–6612 and ISBN 91-7191-388-2. Umeà: UmeA University, 1997.
- Tunstall Pedoe H. The world health organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international colla-boration. J Clin Epidemiol 1988; 41: 105–14.
- Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6.
- Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911–5.
- Masumori N, Tsukamoto T, Kumamoto Y, et al. Japanese men have smaller prostate volumes but com-parable urinary flow rates relative to American men: results of community based studies in 2 countries [see comments]. J Urol 1996; 155: 1324–7.
- Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3–34.
- Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993; 268: 14964–71.
- Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinol-ogy 1998; 139: 807–10.
- Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76: 1005–26.
- Nyomba BL, Berard L, Murphy U. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177–81.
- Hammarsten J, Hiligstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29–36.
- Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997; 145: 970–6.
- Muti P, Trevisan M, Micheli A, et al. Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prey 1996; 5: 917–22.
- de Klerk NH, English DR, Armstrong BK. A review of the effects of random measurement error on relative risk estimates in epidemiological studies. Int J Epidemiol 1989; 18: 705–12.